ImageneBio, Inc.

IMA Healthcare Biotechnology

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.04 0.01 +0.25%
Market cap
$45.7M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−1.12
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
13.24 12.49 18.39 21.47
Net Debt/EBITDA
5.42 16.96 9.84 11.73
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(2.52) (1.48) (1.32) (0.56)
Book value per Share
16.40 27.33 11.00 8.79
Free Cash Flow
(21.49) (7.22) (14.80) (9.07)
Other line items

Show all line items

Columns are period end dates